Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Sepracor Inc. (NasdaqNM:SEPR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
July 23Conference call: Sepracor Earnings (Q2 2001)
Location
111 Locke Drive
Marlborough, MA 01752
Phone: (508) 481-6700
Fax: (508) 481-7683
Email: jbarnes@sepracor.com
Employees (last reported count): 499
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 400 MidCap
Ownership
·Insider and 5%+ Owners: 60%
·Over the last 6 months:
 · one insider buy; 25.0K shares
·Institutional: 90% (226% of float)
(489 institutions)
·Net Inst. Buying: 5.94M shares (+7.77%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Sepracor Inc. is a specialty pharmaceutical company focused on the cost-effective development of potentially safer, purer and more effective drugs that are improved versions of widely prescribed pharmaceutical compounds. The Company develops and markets these drugs by leveraging its expertise in chiral chemistry and pharmacology with its experience in conducting clinical trials and seeking regulatory approvals for new drugs. Sepracor's Improved Chemical Entities pharmaceutical development program has yielded an extensive portfolio of drug candidates intended to treat a broad range of indications in respiratory care, urology, gastroenterology, psychiatry and neurology.
More from Market Guide: Expanded Business Description

Financial Summary
SEPR researches, develops and commercializes products for the synthesis, separation and purification of pharmaceutical compounds. For the six months ended 6/01, revenues rose 58% to $78.2 million. Net loss fell less than 1% to $85.3 million. Revenues reflect an increase in product sales due to the sales of Xopenex. Lower loss was partially offset by increased costs related to several new clinical studies and higher personnel costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Timothy Barberich, 53
Chairman, CEO
$516K$4.9M
William O'Shea, 51
Pres, COO
577K5.8M
David Southwell, 40
CFO, Exec. VP, Sec.
343K26.1M
Robert Scumaci, 41
Exec. VP of Fin. and Admin. Treasurer
275K10.0M
Paul Rubin, M.D., 47
Exec. VP, Drug Devel. and ICE Research
406K19.8M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:SEPRAs of 31-Aug-2001
Price and Volume
52-Week Low
on 4-May-2001
$23.45 
Recent Price$42.70 
52-Week High
on 2-Oct-2000
$124.813
Beta0.71 
Daily Volume (3-month avg)788.4K
Daily Volume (10-day avg)662.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-62.2%
52-Week Change
relative to S&P500
-49.2%
Share-Related Items
Market Capitalization$3.33B
Shares Outstanding77.9M
Float31.2M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 28-Feb-2000
Per-Share Data
Book Value (mrq)-$2.54 
Earnings (ttm)-$2.72 
Earnings (mrq)-$0.48 
Sales (ttm)$1.51 
Cash (mrq)$6.35 
Valuation Ratios
Price/BookN/A 
Price/EarningsN/A 
Price/Sales (ttm)28.22 
Income Statements
Sales (ttm)$114.0M
EBITDA (ttm)-$192.3M
Income available to common (ttm)-$204.0M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-28.07%
Return on EquityN/A 
Financial Strength
Current Ratio (mrq)5.73 
Debt/EquityN/A 
Total Cash (mrq)$494.4M
Short Interest
As of 8-Aug-2001
Shares Short10.0M
Percent of Float32.1%
Shares Short
(Prior Month)
11.0M
Short Ratio13.48 
Daily Volume743.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.